Navigation Links
Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
Date:8/26/2008

Notes Secured by Royalties on U.S. Sales of SANCTURA(R) and SANCTURA XR(TM)

LEXINGTON, Mass., Aug. 26 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that it has closed a private placement to institutional investors of $105.0 million of non-recourse notes (the "Notes"). The Notes are secured by royalties to be paid from sales in the United States of SANCTURA(R) and SANCTURA XR(TM) (trospium chloride). SANCTURA and SANCTURA XR are marketed in the U.S. by Allergan, Inc. for the treatment of overactive bladder (OAB).

"This transaction reflects the successful execution of our plan to improve our balance sheet with non-dilutive financing," said Michael W. Rogers, chief financial officer of Indevus. "With the proceeds from this transaction, we expect to have sufficient cash to retire our outstanding convertible notes, due in July of 2009, and to fund the Company's operations into calendar 2010. In addition, once the Notes are repaid, all royalties will revert to Indevus, thereby providing Indevus with a significant participation in the future royalty stream of the product. Importantly, this transaction does not cover royalties on SANCTURA XR that we expect to receive on sales in Europe and other territories around the world."

The Notes will bear interest at 16% per annum payable quarterly beginning November 5, 2008. All excess royalties, after paying interest, administrative fees, and applicable tax distributions, will be applied to the principal of the Notes until the Notes have been paid in full. From the proceeds of the transaction, Indevus will establish a $10.0 million interest reserve account to cover any potential shortfall in interest payments. After two years, any remaining funds
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/57b5qj/global_pdt ... "Global PDT Machine Industry Report 2014" report ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The Global PDT ... in-depth study on the current state of the ... overview of the industry including definitions, classifications, applications ...
(Date:6/1/2015)...  Boston-based Veritas Genetics is launching its mission ... personalized medicine and prevention to the forefront, allowing ... Beginning with its first product, a genetic screen ... Genetics is making its products affordable and accessible, ... genetic data which will be shared with the ...
(Date:6/1/2015)... ROUGE, La. , June 1, 2015 ... Phase II trial of lead candidate EP-100 in ovarian ... membrane-disrupting peptide designed to seek and destroy cancer cells ... surfaces. LHRH receptors are over-expressed in a wide range ... randomized, multi-center Phase II trial of EP-100 were ...
(Date:6/1/2015)... -- Shire plc (LSE: SHP, NASDAQ: ... the Jefferies 2015 Global Healthcare Conference in ... 2015. Jeff Poulton , Chief Financial Officer will ... a.m. ET (3:00 p.m. BST). A live ... Webcasts section of Shire,s Investor website at http://investors.shire.com/presentations-and-webcasts/year-2015.aspx ...
Breaking Biology Technology:Global PDT Machine Industry Report 2014 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... ... camera during an operation he performed for his Discovery Channel television special: Silent Stalker: ... ... Show used VizVOCUS,s popular "plug and play" medical camera during an ...
... England , May 25, 2010 Executives from Heptares,Therapeutics (Welwyn ... of the agreement under which O2h provides multi-FTE -synthetic,chemistry services to support ... , ... said, "We are happy to have signed,this new contract with O2h; they ...
... China , May 25 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: ... leading over-the-counter Hepatitis B medicine,Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), ... it has,commenced assembly of its production line for its proprietary Zushima ... ...
Cached Biology Technology:VizVOCUS's Digital Camera Used by Dr. Mehmet Oz on Discovery Channel Special 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 2Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h) 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 2Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 3Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line 4
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Mayo Clinic-led researchers is first to devise a system ... killer that hunts down and destroys cancer cells -- ... an advanced electronic article of Nature Biotechnology. , The ... cells, and then redirected the virus to attack diseased, ...
... prenatal care, new research suggests that early infection may ... on the immune system. Researchers at the University of ... a one-time infection as newborns didn't learn as well ... after their immunity was challenged. The research is in ...
... that the antibiotic minocycline might help alleviate HIV's negative ... that can develop even though antiretroviral therapy controls the ... with simian immunodeficiency virus (SIV), a very close relative ... to brain cells, less brain inflammation, and less virus ...
Cached Biology News:Mayo Clinic Researchers Create 'Obedient Virus'; First Step To Use Measles Virus Against Cancer 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 3Antibiotic might fight HIV-induced neurological problems 2Antibiotic might fight HIV-induced neurological problems 3
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Vybrant® Multidrug Resistance Assay Kit...
... Platypus Contact Printing Kit contains choice ... with series of 100 / 200 micron ... or 200 um x 10 mm lines, ... 20, 40 or 60 nm and pitch ...
Request Info...
Biology Products: